Invasive group A streptococcal disease surveillance in Canada, 2020.

Alyssa Golden, Averil Griffith, Walter Demczuk, Gregory Tyrrell, Julianne Kus, Allison McGeer, Marc-Christian Domingo, Linda Hoang, Jessica Minion, Paul Van Caeseele, Hanan Smadi, David Haldane, George Zahariadis, Kristen Mead, Laura Steven, Lori Strudwick, Anita Li, Michael Mulvey, Irene Martin
Author Information
  1. Alyssa Golden: National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.
  2. Averil Griffith: National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.
  3. Walter Demczuk: National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.
  4. Gregory Tyrrell: Provincial Laboratory for Public Health (Microbiology), Edmonton, AB.
  5. Julianne Kus: Public Health Ontario, Toronto, ON.
  6. Allison McGeer: Toronto Invasive Bacterial Diseases Network (TIBDN), Department of Microbiology, Mount Sinai Hospital, Toronto, ON.
  7. Marc-Christian Domingo: Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de- Bellevue, QC.
  8. Linda Hoang: British Columbia Centre for Disease Control, Vancouver, BC.
  9. Jessica Minion: Roy Romanow Provincial Laboratory, Regina, SK.
  10. Paul Van Caeseele: Cadham Provincial Laboratory, Winnipeg, MB.
  11. Hanan Smadi: New Brunswick Department of Health, Fredericton, NB.
  12. David Haldane: Queen Elizabeth II Health Science Centre, Halifax, NS.
  13. George Zahariadis: Newfoundland and Labrador Public Health Laboratory, St. John's, NL.
  14. Kristen Mead: Queen Elizabeth Hospital, Charlottetown, PE.
  15. Laura Steven: Stanton Territorial Hospital Laboratory, Yellowknife, NT.
  16. Lori Strudwick: Yukon Communicable Disease Control, Whitehorse, YT.
  17. Anita Li: Centre for Immunization & Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
  18. Michael Mulvey: National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.
  19. Irene Martin: National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.

Abstract

Background: Invasive group A streptococcal (iGAS) disease (caused by ) has been a nationally notifiable disease in Canada since 2000. This report summarizes the demographics, types and antimicrobial resistance of iGAS infections in Canada in 2020.
Methods: The Public Health Agency of Canada's National Microbiology Laboratory (Winnipeg, Manitoba) collaborates with provincial and territorial public health laboratories to conduct national surveillance of invasive typing was performed on all isolates using the Centers for Disease Control and Prevention sequencing protocol. Antimicrobial susceptibilities were determined using Kirby-Bauer disk diffusion according to Clinical and Laboratory Standards Institute guidelines. Population-based iGAS disease incidence rates up to 2019 were obtained through the Canadian Notifiable Disease Surveillance System.
Results: Overall, the incidence of iGAS disease in Canada has increased from 4.0 to 8.1 cases per 100,000 population from 2009 to 2019. The 2019 incidence represents a slight decrease from the 2018 rate of 8.6 cases per 100,000 population. A total of 2,867 invasive isolates that were collected during 2020 are included in this report, representing a decrease from 2019 (n=3,194). The most common types in 2020 were 49 (16.8%, n=483) and 76 (15.0%, n=429), both increasing significantly in prevalence since 2016 (<0.001). The former most prevalent type, 1, decreased to 7.6% (n=217) in 2020 from 15.4% (n=325) in 2016. Antimicrobial resistance rates in 2020 included 11.5% resistance to erythromycin, 3.2% resistance to clindamycin and 1.6% nonsusceptibility to chloramphenicol.
Conclusion: Though the number of collected invasive isolates decreased slightly in 2020 in comparison to previous years, iGAS disease remains an important public health concern. The distribution in Canada has been subtly shifting over the past five years, away from common and well-known 1 and towards 49 and 76. It is important to continue surveillance of in Canada to monitor expanding replacement types, as well as outbreak clones and antimicrobial resistance.

Keywords

References

  1. Vaccine. 2020 Feb 5;38(6):1384-1392 [PMID: 31843270]
  2. Lancet Infect Dis. 2020 May;20(5):538-539 [PMID: 32359463]
  3. Open Forum Infect Dis. 2018 Apr 20;5(5):ofy085 [PMID: 29780850]
  4. Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1768-76 [PMID: 24733896]
  5. J Infect. 2019 Nov;79(5):435-443 [PMID: 31419474]
  6. Lancet Infect Dis. 2019 Nov;19(11):1209-1218 [PMID: 31519541]
  7. Clin Infect Dis. 2021 Dec 6;73(11):e3718-e3726 [PMID: 32803254]
  8. Mil Med. 2019 Mar 1;184(3-4):e197-e204 [PMID: 30137490]
  9. Pediatr Infect Dis J. 2021 Jul 1;40(7):612-616 [PMID: 34097654]
  10. Lancet Digit Health. 2021 Jun;3(6):e360-e370 [PMID: 34045002]
  11. Lancet Infect Dis. 2020 May;20(5):539-540 [PMID: 32359464]
  12. mBio. 2019 Dec 10;10(6): [PMID: 31822586]
  13. Eur J Clin Microbiol Infect Dis. 2021 Nov;40(11):2295-2303 [PMID: 34046804]
  14. Front Public Health. 2018 Mar 09;6:59 [PMID: 29662874]
  15. Public Health. 2020 Sep;186:63-70 [PMID: 32784097]
  16. Curr Top Microbiol Immunol. 2013;368:1-27 [PMID: 23242849]
  17. Clin Infect Dis. 2018 Mar 19;66(7):1068-1074 [PMID: 29069346]
  18. mSystems. 2021 Aug 31;6(4):e0049521 [PMID: 34374563]
  19. Lancet Infect Dis. 2019 Dec;19(12):1284-1285 [PMID: 31782392]
  20. mBio. 2015 Jul 14;6(4):e00622 [PMID: 26173696]
  21. Clin Microbiol Rev. 2014 Apr;27(2):264-301 [PMID: 24696436]
  22. Clin Infect Dis. 2021 Dec 6;73(11):1957-1964 [PMID: 34170310]
  23. Pediatr Infect Dis J. 2021 Aug 1;40(8):e313-e316 [PMID: 34250979]

Word Cloud

Created with Highcharts 10.0.0Canada2020iGASdiseaseresistancesurveillance20191grouptypesantimicrobialinvasiveisolatesincidenceInvasivestreptococcalsincereportLaboratorypublichealthusingDiseaseAntimicrobialrates8casesper100000populationdecreasecollectedincludedcommon4976152016decreased6%yearsimportantBackground:causednationallynotifiable2000summarizesdemographicsinfectionsMethods:PublicHealthAgencyCanada'sNationalMicrobiologyWinnipegManitobacollaboratesprovincialterritoriallaboratoriesconductnationaltypingperformedCentersControlPreventionsequencingprotocolsusceptibilitiesdeterminedKirby-BauerdiskdiffusionaccordingClinicalStandardsInstituteguidelinesPopulation-basedobtainedCanadianNotifiableSurveillanceSystemResults:Overallincreased402009representsslight2018rate6total2867representingn=3194168%n=4830%n=429increasingsignificantlyprevalence<0001formerprevalenttype7n=2174%n=325115%erythromycin32%clindamycinnonsusceptibilitychloramphenicolConclusion:Thoughnumberslightlycomparisonpreviousremainsconcerndistributionsubtlyshiftingpastfiveawaywell-knowntowardscontinuemonitorexpandingreplacementwelloutbreakclonesStreptococcuspyogenesemmstreptococcus

Similar Articles

Cited By